Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

Documenti analoghi

• Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination
  di: Vrtala, Susanne, et al.
  Pubblicazione: (2011)
• Random mutagenesis and phage display technology as a tool for identifying ige epitopes of the birch pollen allergen Bet v 1
  di: Guhsl, Elisabeth Eva, et al.
  Pubblicazione: (2014)
• Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy
  di: Linhart, B, et al.
  Pubblicazione: (2014)
• Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1
  di: BAUER, L, et al.
  Pubblicazione: (1997)
• Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms
  di: Campana, Raffaela, et al.
  Pubblicazione: (2018)